Pfizer (PFE) – An Investor's Strategic Perspective

By Emilio Sanchez • Monday, October 06 15:32 • Permanent Link

Large-cap Health Care company Pfizer has moved -3.0% so far today on a volume of 47,181,024, compared to its average of 47,867,395. In contrast, the S&P 500 index moved 0.0%.

Pfizer trades -7.95% away from its average analyst target price of $28.85 per share. The 22 analysts following the stock have set target prices ranging from $24.0 to $36.0, and on average have given Pfizer a rating of buy.

Anyone interested in buying PFE should be aware of the facts below:

Pfizer's current price is 19.9% above its Graham number of $22.16, which implies that at its current valuation it does not offer a margin of safety
Pfizer has moved -6.3% over the last year, and the S&P 500 logged a change of 17.9%
Based on its trailing earnings per share of 1.89, Pfizer has a trailing 12 month Price to Earnings (P/E) ratio of 14.1 while the S&P 500 average is 29.3
PFE has a forward P/E ratio of 9.1 based on its forward 12 month price to earnings (EPS) of $2.93 per share
Its Price to Book (P/B) ratio is 1.7 compared to its sector average of 3.19
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Based in New York, the company has 81,000 full time employees and a market cap of $151.01 Billion. Pfizer currently returns an annual dividend yield of 6.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.